Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system

First-line anti-PD-1 therapy significantly improved overall and switch-free survival compared with cetuximab, used alone or in combination with chemotherapy. These findings provide robust real-world evidence supporting anti-PD-1 agents as the preferred first-line systemic treatment for acSCC in dermatologic oncology practice.